ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV1701/Vitargus) under development.
For its drug products, the company utilizes unlicensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. Its network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus, the company intends to conduct global clinical trials through Phase III.